- Home
- AKBA vs PRME Comparison
AKBA vs PRME Comparison
Compare AKBA & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- PRME
- Stock Information
- Founded
- AKBA 2007
- PRME 2019
- Country
- AKBA United States
- PRME United States
- Employees
- AKBA N/A
- PRME N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- PRME Medicinal Chemicals and Botanical Products
- Sector
- AKBA Health Care
- PRME Health Care
- Exchange
- AKBA Nasdaq
- PRME Nasdaq
- Market Cap
- AKBA 729.1M
- PRME 693.5M
- IPO Year
- AKBA 2014
- PRME 2022
- Fundamental
- Price
- AKBA $3.09
- PRME $4.82
- Analyst Decision
- AKBA Strong Buy
- PRME Buy
- Analyst Count
- AKBA 5
- PRME 6
- Target Price
- AKBA $6.90
- PRME $8.88
- AVG Volume (30 Days)
- AKBA 2.6M
- PRME 4.3M
- Earning Date
- AKBA 11-06-2025
- PRME 11-11-2025
- Dividend Yield
- AKBA N/A
- PRME N/A
- EPS Growth
- AKBA N/A
- PRME N/A
- EPS
- AKBA N/A
- PRME N/A
- Revenue
- AKBA $203,733,000.00
- PRME $4,961,000.00
- Revenue This Year
- AKBA $43.91
- PRME $179.58
- Revenue Next Year
- AKBA $32.09
- PRME N/A
- P/E Ratio
- AKBA N/A
- PRME N/A
- Revenue Growth
- AKBA 16.75
- PRME 739.42
- 52 Week Low
- AKBA $1.52
- PRME $1.11
- 52 Week High
- AKBA $4.08
- PRME $6.94
- Technical
- Relative Strength Index (RSI)
- AKBA 59.78
- PRME 44.51
- Support Level
- AKBA $2.93
- PRME $4.77
- Resistance Level
- AKBA $3.19
- PRME $5.55
- Average True Range (ATR)
- AKBA 0.13
- PRME 0.56
- MACD
- AKBA 0.04
- PRME -0.18
- Stochastic Oscillator
- AKBA 91.92
- PRME 7.71
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.